stockportfolio.pro
Stocks / EMBC vs UPB
EMBC vs UPB
Embecta Corp. and Upstream Bio, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Embecta Corp. (EMBC) | Upstream Bio, Inc. (UPB) | |
|---|---|---|
| Market cap | $0.2B | $0.3B |
| Revenue (latest FY) | $1.08B | $2.85M |
| Net income (latest FY) | $95.40M | $-143.44M |
| Revenue growth (5y CAGR) | -0.1% | 33.0% |
| Net margin | 8.8% | -5026.0% |
| Return on equity | -14.7% | -42.2% |
| P/E ratio | 1.7 | — |
| Dividend yield | 13.9% | — |
| Profitable years (of last 10) | 6 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EMBC — free Open UPB — freeFrequently asked questions
Which is bigger, EMBC or UPB?
Upstream Bio, Inc. is larger by market capitalization — $0.3B versus $0.2B.
Which grows faster, EMBC or UPB?
Over the last five fiscal years, Upstream Bio, Inc. grew revenue faster — 33.0%/yr versus -0.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.